Novo Holdings to Acquire Catalent for ~$16.5B
Shots:
- Novo Holdings to acquire Catalent in an all-cash transaction with a total enterprise value of ~$16.5B
- As a part of the transaction, Catalent common stockholders will receive $63.50/share in cash, reflecting a premium of approximately 47.5% over the 60-day volume-weighted average price as of February 2, 2024
- Moreover, out of 50 Catalent global sites, Novo Holdings plans to sell 3 fill-finish sites (Italy, USA, Belgium) & related assets acquired from Catalent to Novo Nordisk
Ref: Catalent | Image: Catalent
Related News:- Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
